Leucemia linfoblástica aguda estirpe B Philadelphia negativa en adolescentes y adultos jóvenes: Resultados del Protocolo Terapéutico LLA 15-30, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile

Background: Intensified treatment of Philadelphia chromosome negative acute lymphoblastic leukemia (Ph(-)ALL) in adolescents by pediatric teams, with fve years disease free survival (DFS) rate of 65%, encouraged the use of intensified protocols in patients between 15 and 30 years, improving the DFS from 45% to 60-80%. The protocol LLA 15-30 for patients between 15 and 30 years with Ph(-)ALL, based on the Children’s Oncology Group (COG) protocol AALL0232 resulting in a five years DFS of 78%, was started in 2007 by the PANDA national program. Aim: To report the results of the prospective cohort study evaluating the results of this protocol four years after its implementation. Patients and Methods: Between January 2007 and December 2010, 68 Ph(-) ALL patients, aged between 15-30 years (75% males) were incorporated. Survival was evaluated using Kaplan-Meier and log-rank tests. Results: Fifty percent of patients were of high risk. A complete response was achieved in 91%, early death occurred in 6% and induction failure in 3%. Median follow-up was 23 months. Overall survival, disease free survival and relapse rates at 35 months were 61.8, 67.5% and 31% respectively. Conclusions: LLA 15-30 protocol significantly improved three-year overall survival from 31 to 62%. The 20% difference observed with AALL0232 protocol is explained by the high rate of relapse. Improving provider and patient compliance with protocols may eliminate this gap.

Saved in:
Bibliographic Details
Main Authors: Puga,Bárbara, Guerra,Carolina, Molina,Javiera, Cabrera,María Elena, Pilleux,Lilian, Calderón,Susana, Rojas,Christine, Vergara,Carmen Gloria, Rojas,Hernán, Muñoz,Lina, Lois,Vivianne, Aspillaga,Augusto, Pizarro,Álvaro
Format: Digital revista
Language:Spanish / Castilian
Published: Sociedad Médica de Santiago 2014
Online Access:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000600004
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0034-98872014000600004
record_format ojs
spelling oai:scielo:S0034-988720140006000042014-11-06Leucemia linfoblástica aguda estirpe B Philadelphia negativa en adolescentes y adultos jóvenes: Resultados del Protocolo Terapéutico LLA 15-30, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, ChilePuga,BárbaraGuerra,CarolinaMolina,JavieraCabrera,María ElenaPilleux,LilianCalderón,SusanaRojas,ChristineVergara,Carmen GloriaRojas,HernánMuñoz,LinaLois,VivianneAspillaga,AugustoPizarro,Álvaro Adolescent Adult Antineoplastic protocols Precursor cell lymphoblastic Leukemia-Lymphoma Background: Intensified treatment of Philadelphia chromosome negative acute lymphoblastic leukemia (Ph(-)ALL) in adolescents by pediatric teams, with fve years disease free survival (DFS) rate of 65%, encouraged the use of intensified protocols in patients between 15 and 30 years, improving the DFS from 45% to 60-80%. The protocol LLA 15-30 for patients between 15 and 30 years with Ph(-)ALL, based on the Children’s Oncology Group (COG) protocol AALL0232 resulting in a five years DFS of 78%, was started in 2007 by the PANDA national program. Aim: To report the results of the prospective cohort study evaluating the results of this protocol four years after its implementation. Patients and Methods: Between January 2007 and December 2010, 68 Ph(-) ALL patients, aged between 15-30 years (75% males) were incorporated. Survival was evaluated using Kaplan-Meier and log-rank tests. Results: Fifty percent of patients were of high risk. A complete response was achieved in 91%, early death occurred in 6% and induction failure in 3%. Median follow-up was 23 months. Overall survival, disease free survival and relapse rates at 35 months were 61.8, 67.5% and 31% respectively. Conclusions: LLA 15-30 protocol significantly improved three-year overall survival from 31 to 62%. The 20% difference observed with AALL0232 protocol is explained by the high rate of relapse. Improving provider and patient compliance with protocols may eliminate this gap.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.142 n.6 20142014-06-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000600004es10.4067/S0034-98872014000600004
institution SCIELO
collection OJS
country Chile
countrycode CL
component Revista
access En linea
databasecode rev-scielo-cl
tag revista
region America del Sur
libraryname SciELO
language Spanish / Castilian
format Digital
author Puga,Bárbara
Guerra,Carolina
Molina,Javiera
Cabrera,María Elena
Pilleux,Lilian
Calderón,Susana
Rojas,Christine
Vergara,Carmen Gloria
Rojas,Hernán
Muñoz,Lina
Lois,Vivianne
Aspillaga,Augusto
Pizarro,Álvaro
spellingShingle Puga,Bárbara
Guerra,Carolina
Molina,Javiera
Cabrera,María Elena
Pilleux,Lilian
Calderón,Susana
Rojas,Christine
Vergara,Carmen Gloria
Rojas,Hernán
Muñoz,Lina
Lois,Vivianne
Aspillaga,Augusto
Pizarro,Álvaro
Leucemia linfoblástica aguda estirpe B Philadelphia negativa en adolescentes y adultos jóvenes: Resultados del Protocolo Terapéutico LLA 15-30, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile
author_facet Puga,Bárbara
Guerra,Carolina
Molina,Javiera
Cabrera,María Elena
Pilleux,Lilian
Calderón,Susana
Rojas,Christine
Vergara,Carmen Gloria
Rojas,Hernán
Muñoz,Lina
Lois,Vivianne
Aspillaga,Augusto
Pizarro,Álvaro
author_sort Puga,Bárbara
title Leucemia linfoblástica aguda estirpe B Philadelphia negativa en adolescentes y adultos jóvenes: Resultados del Protocolo Terapéutico LLA 15-30, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile
title_short Leucemia linfoblástica aguda estirpe B Philadelphia negativa en adolescentes y adultos jóvenes: Resultados del Protocolo Terapéutico LLA 15-30, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile
title_full Leucemia linfoblástica aguda estirpe B Philadelphia negativa en adolescentes y adultos jóvenes: Resultados del Protocolo Terapéutico LLA 15-30, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile
title_fullStr Leucemia linfoblástica aguda estirpe B Philadelphia negativa en adolescentes y adultos jóvenes: Resultados del Protocolo Terapéutico LLA 15-30, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile
title_full_unstemmed Leucemia linfoblástica aguda estirpe B Philadelphia negativa en adolescentes y adultos jóvenes: Resultados del Protocolo Terapéutico LLA 15-30, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile
title_sort leucemia linfoblástica aguda estirpe b philadelphia negativa en adolescentes y adultos jóvenes: resultados del protocolo terapéutico lla 15-30, programa nacional de cáncer del adulto (panda), ministerio de salud, chile
description Background: Intensified treatment of Philadelphia chromosome negative acute lymphoblastic leukemia (Ph(-)ALL) in adolescents by pediatric teams, with fve years disease free survival (DFS) rate of 65%, encouraged the use of intensified protocols in patients between 15 and 30 years, improving the DFS from 45% to 60-80%. The protocol LLA 15-30 for patients between 15 and 30 years with Ph(-)ALL, based on the Children’s Oncology Group (COG) protocol AALL0232 resulting in a five years DFS of 78%, was started in 2007 by the PANDA national program. Aim: To report the results of the prospective cohort study evaluating the results of this protocol four years after its implementation. Patients and Methods: Between January 2007 and December 2010, 68 Ph(-) ALL patients, aged between 15-30 years (75% males) were incorporated. Survival was evaluated using Kaplan-Meier and log-rank tests. Results: Fifty percent of patients were of high risk. A complete response was achieved in 91%, early death occurred in 6% and induction failure in 3%. Median follow-up was 23 months. Overall survival, disease free survival and relapse rates at 35 months were 61.8, 67.5% and 31% respectively. Conclusions: LLA 15-30 protocol significantly improved three-year overall survival from 31 to 62%. The 20% difference observed with AALL0232 protocol is explained by the high rate of relapse. Improving provider and patient compliance with protocols may eliminate this gap.
publisher Sociedad Médica de Santiago
publishDate 2014
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000600004
work_keys_str_mv AT pugabarbara leucemialinfoblasticaagudaestirpebphiladelphianegativaenadolescentesyadultosjovenesresultadosdelprotocoloterapeuticolla1530programanacionaldecancerdeladultopandaministeriodesaludchile
AT guerracarolina leucemialinfoblasticaagudaestirpebphiladelphianegativaenadolescentesyadultosjovenesresultadosdelprotocoloterapeuticolla1530programanacionaldecancerdeladultopandaministeriodesaludchile
AT molinajaviera leucemialinfoblasticaagudaestirpebphiladelphianegativaenadolescentesyadultosjovenesresultadosdelprotocoloterapeuticolla1530programanacionaldecancerdeladultopandaministeriodesaludchile
AT cabreramariaelena leucemialinfoblasticaagudaestirpebphiladelphianegativaenadolescentesyadultosjovenesresultadosdelprotocoloterapeuticolla1530programanacionaldecancerdeladultopandaministeriodesaludchile
AT pilleuxlilian leucemialinfoblasticaagudaestirpebphiladelphianegativaenadolescentesyadultosjovenesresultadosdelprotocoloterapeuticolla1530programanacionaldecancerdeladultopandaministeriodesaludchile
AT calderonsusana leucemialinfoblasticaagudaestirpebphiladelphianegativaenadolescentesyadultosjovenesresultadosdelprotocoloterapeuticolla1530programanacionaldecancerdeladultopandaministeriodesaludchile
AT rojaschristine leucemialinfoblasticaagudaestirpebphiladelphianegativaenadolescentesyadultosjovenesresultadosdelprotocoloterapeuticolla1530programanacionaldecancerdeladultopandaministeriodesaludchile
AT vergaracarmengloria leucemialinfoblasticaagudaestirpebphiladelphianegativaenadolescentesyadultosjovenesresultadosdelprotocoloterapeuticolla1530programanacionaldecancerdeladultopandaministeriodesaludchile
AT rojashernan leucemialinfoblasticaagudaestirpebphiladelphianegativaenadolescentesyadultosjovenesresultadosdelprotocoloterapeuticolla1530programanacionaldecancerdeladultopandaministeriodesaludchile
AT munozlina leucemialinfoblasticaagudaestirpebphiladelphianegativaenadolescentesyadultosjovenesresultadosdelprotocoloterapeuticolla1530programanacionaldecancerdeladultopandaministeriodesaludchile
AT loisvivianne leucemialinfoblasticaagudaestirpebphiladelphianegativaenadolescentesyadultosjovenesresultadosdelprotocoloterapeuticolla1530programanacionaldecancerdeladultopandaministeriodesaludchile
AT aspillagaaugusto leucemialinfoblasticaagudaestirpebphiladelphianegativaenadolescentesyadultosjovenesresultadosdelprotocoloterapeuticolla1530programanacionaldecancerdeladultopandaministeriodesaludchile
AT pizarroalvaro leucemialinfoblasticaagudaestirpebphiladelphianegativaenadolescentesyadultosjovenesresultadosdelprotocoloterapeuticolla1530programanacionaldecancerdeladultopandaministeriodesaludchile
_version_ 1755988458249125888